Despite its benefits, the BPCA also faces some challenges. One issue is that not all drug manufacturers opt to take advantage of the incentives, leaving gaps in research for certain medications. Additionally, conducting pediatric studies can be complex and costly, and there may be ethical considerations when involving children in clinical trials. The BPCA also does not mandate studies but rather provides voluntary incentives, which can limit its overall impact.
